Our group investigates key aspects of vascular biology, atherothrombosis and myocardial pathophysiology geared towards the characterization of the cellular and molecular mechanisms involved in the onset, progression and complication of atherotrombotic diseases (ischemic heart disease (IHD) and peripheral artery disease (PAD)), abdominal aortic aneurysm (AAA) and cardiac hypertrophy. The group analyses the role of NR4A nuclear receptors, in particular NOR-1 (NR4A3), and lysyl oxidases (LOX) in these pathologies using multidisciplinary and translational approaches. Our ultimate goal is to identify novel therapeutic targets and biomarkers to better manage these highly prevalent diseases.
The specific objectives pursued are:
Our findings in 2019 have uncovered (i) the relevant role of NOR-1 in the pathological remodelling involved in hypertensive cardiac hypertrophy, establishing a new mouse model, for this disease, and (ii) how NR4A receptors participate in the signalling pathway of CD69, an immunomodulatory molecule that we identified as a new receptor for oxidized LDL and an early biomarker of subclinical atherosclerosis.